1) The prognosis for refractory/relapsed LBCL not suitable for curative treatment is poor. The success of CD20×CD3 TCE mosunetuzumab combined with CD79b ADC polatuzumab vedotin in Phase 3 has provided patients with a novel, fixed-cycle, outpatient therapy. (Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial)In … Read more
Diffuse Large B-Cell Lymphoma: Composed of centroblastic (non-cleaved), B immunoblastic, and anaplastic large B-cell lymphomas classified by Kiel. Under the microscope: a relatively uniform morphology of large cells arranged diffusely can be seen. The cell morphology is diverse, resembling centroblasts, immunoblasts, and may also include multinucleated tumor cells with anaplastic features. Incidence Rate Diffuse large … Read more
From May 30 to June 3, 2025, the largest global oncology conference, the American Society of Clinical Oncology (ASCO) Annual Meeting, was held in Chicago, USA. Researchers including Philippe Armand presented data from the waveLINE-003 Phase II study, exploring the recommended treatment dose, safety, and efficacy of the novel antibody-drug conjugate (ADC) Zilovertamab vedotin (ZV) … Read more
At the recent 2025 European Hematology Association (EHA) Annual Meeting and the International Conference on Malignant Lymphoma (ICML), not only were continuous breakthroughs in the field of lymphoma treatment witnessed, but a series of studies also validated the immense potential of precision immunotherapy in enhancing patient survival benefits. “Blood News” focuses on this international event, … Read more
Organized by: Oncology Information Source: Oncology Information Recently, a prospective study published by Professor Zhang Mingzhi, Professor Chen Qingjiang, and Professor Zhang Xudong from Zhengzhou University First Affiliated Hospital in Frontiers in Oncology (impact factor 6.244) evaluated the efficacy and safety of decitabine (DAC) combined with cisplatin, cytarabine, and dexamethasone (DHAP) modified regimen in patients … Read more